อ้างอิง ของ โรคอัลไซเมอร์

  1. 1 2 3 4 5 6 7 8 9 10 Burns A, Iliffe S (February 2009). "Alzheimer's disease". BMJ. 338: b158. doi:10.1136/bmj.b158. PMID 19196745.
  2. 1 2 3 4 5 6 7 "Dementia Fact sheet". World Health Organization. 12 December 2017.
  3. 1 2 Mendez MF (November 2012). "Early-onset Alzheimer's disease: nonamnestic subtypes and type 2 AD". Archives of Medical Research. 43 (8): 677–85. doi:10.1016/j.arcmed.2012.11.009. PMC 3532551. PMID 23178565.
  4. 1 2 3 4 5 Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (March 2011). "Alzheimer's disease". Lancet. 377 (9770): 1019–31. doi:10.1016/S0140-6736(10)61349-9. PMID 21371747.
  5. 1 2 "Dementia diagnosis and assessment" (PDF). National Institute for Health and Care Excellence (NICE). Archived from the original (PDF) on 5 December 2014. สืบค้นเมื่อ 30 November 2014.
  6. 1 2 Commission de la transparence (June 2012). "Drugs for Alzheimer's disease: best avoided. No therapeutic advantage" [Drugs for Alzheimer's disease: best avoided. No therapeutic advantage]. Prescrire International. 21 (128): 150. PMID 22822592.
  7. 1 2 Querfurth HW, LaFerla FM (January 2010). "Alzheimer's disease". The New England Journal of Medicine. 362 (4): 329–44. doi:10.1056/NEJMra0909142. PMID 20107219.
  8. 1 2 GBD 2015 Disease Injury Incidence Prevalence Collaborators (October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.
  9. 1 2 GBD 2015 Mortality Causes of Death Collaborators (October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/S0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
  10. ↑ ศัพท์บัญญัติราชบัณฑิตยสถาน ข้อมูลปรับปรุงวันที่ 6 สิงหาคม พ.ศ. 2544 เรียกดูเมื่อ 11 เมษายน พ.ศ. 2552
  11. ↑ บัญชีจำแนกโรคระหว่างประเทศ ฉบับประเทศไทย (อังกฤษ-ไทย) ฉบับปี 2009. สำนักนโยบายและยุทธศาสตร์ สำนักงานปลัดกระทรวงสาธารณสุข, 2552.
  12. ↑ "About Alzheimer's Disease: Symptoms". National Institute on Aging. Archived from the original on 15 January 2012. สืบค้นเมื่อ 28 December 2011.
  13. ↑ Todd S, Barr S, Roberts M, Passmore AP (November 2013). "Survival in dementia and predictors of mortality: a review". International Journal of Geriatric Psychiatry. 28 (11): 1109–24. doi:10.1002/gps.3946. PMID 23526458.
  14. ↑ "So, What Can You Do?". National Institute on Aging. 29 July 2016. Archived from the original on 3 April 2017.
  15. 1 2 3 4 Hsu D, Marshall GA (2017). "Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward". Current Alzheimer Research. 14 (4): 426–40. doi:10.2174/1567205013666160930112125. PMC 5329133. PMID 27697063.
  16. 1 2 3 4 Thompson CA, Spilsbury K, Hall J, Birks Y, Barnes C, Adamson J (July 2007). "Systematic review of information and support interventions for caregivers of people with dementia". BMC Geriatrics. 7: 18. doi:10.1186/1471-2318-7-18. PMC 1951962. PMID 17662119.
  17. ↑ Forbes D, Forbes SC, Blake CM, Thiessen EJ, Forbes S (April 2015). "Exercise programs for people with dementia". The Cochrane Database of Systematic Reviews (Submitted manuscript). 132 (4): CD006489. doi:10.1002/14651858.CD006489.pub4. PMID 25874613.
  18. ↑ National Institute for Health and Clinical Excellence. "Low-dose antipsychotics in people with dementia". National Institute for Health and Care Excellence (NICE). Archived from the original on 5 December 2014. สืบค้นเมื่อ 29 November 2014.
  19. ↑ "Information for Healthcare Professionals: Conventional Antipsychotics". US Food and Drug Administration. 16 June 2008. Archived from the original on 29 November 2014. สืบค้นเมื่อ 29 November 2014.
  20. 1 2 3 Bonin-Guillaume S, Zekry D, Giacobini E, Gold G, Michel JP (January 2005). "[The economical impact of dementia]". Presse Médicale (in French). 34 (1): 35–41. doi:10.1016/s0755-4982(05)83882-5. PMID 15685097.CS1 maint: Unrecognized language (link)
  21. 1 2 3 4 5 Meek PD, McKeithan K, Schumock GT (1998). "Economic considerations in Alzheimer's disease". Pharmacotherapy. 18 (2 Pt 2): 68–73, discussion 79–82. doi:10.1002/j.1875-9114.1998.tb03880.x (inactive 2019-07-19). PMID 9543467.
  22. ↑ "Evaluating Prescription Drugs Used to Treat: Alzheimer's Disease Comparing Effectiveness, Safety, and Price" (PDF). Consumer Reports Drug Effectiveness Review Project. Consumer Reports. May 2012. Archived (PDF) from the original on 5 September 2012. สืบค้นเมื่อ 1 May 2013.
  23. 1 2 3 4 5 Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, Scheltens P, Tariska P, Winblad B (January 2007). "Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline". European Journal of Neurology. 14 (1): e1–26. doi:10.1111/j.1468-1331.2006.01605.x. PMID 17222085.
  24. ↑ Bäckman L, Jones S, Berger AK, Laukka EJ, Small BJ (September 2004). "Multiple cognitive deficits during the transition to Alzheimer's disease". Journal of Internal Medicine. 256 (3): 195–204. doi:10.1111/j.1365-2796.2004.01386.x. PMID 15324363.
  25. ↑ Perneczky R, Pohl C, Sorg C, Hartmann J, Komossa K, Alexopoulos P, Wagenpfeil S, Kurz A (2006). "Complex activities of daily living in mild cognitive impairment: conceptual and diagnostic issues". Age Ageing. 35 (3): 240–245. doi:10.1093/ageing/afj054. PMID 16513677.CS1 maint: Multiple names: authors list (link)
  26. ↑ Arnáiz E, Almkvist O (2003). "Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease". Acta Neurol. Scand., Suppl. 179: 34–41. doi:10.1034/j.1600-0404.107.s179.7.x. PMID 12603249. |access-date= requires |url= (help)
  27. ↑ Kazui H, Matsuda A, Hirono N; และคณะ (2005). "Everyday memory impairment of patients with mild cognitive impairment". Dement Geriatr Cogn Disord. 19 (5–6): 331–7. doi:10.1159/000084559. PMID 15785034. สืบค้นเมื่อ 2008-06-12.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
  28. ↑ Rapp MA, Reischies FM (2005). "Attention and executive control predict Alzheimer disease in late life: results from the Berlin Aging Study (BASE)". American Journal of Geriatric Psychiatry. 13 (2): 134–141. doi:10.1176/appi.ajgp.13.2.134. PMID 15703322.
  29. ↑ Spaan PE, Raaijmakers JG, Jonker C (2003). "Alzheimer's disease versus normal ageing: a review of the efficiency of clinical and experimental memory measures". Journal of Clinical Experimental Neuropsychology. 25 (2): 216–233. doi:10.1076/jcen.25.2.216.13638. PMID 12754679.CS1 maint: Multiple names: authors list (link)
  30. ↑ Craig D, Mirakhur A, Hart DJ, McIlroy SP, Passmore AP (2005). "A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease". American Journal of Geriatric Psychiatry. 13 (6): 460–468. doi:10.1176/appi.ajgp.13.6.460. PMID 15956265.CS1 maint: Multiple names: authors list (link)
  31. ↑ Robert PH, Berr C, Volteau M, Bertogliati C, Benoit M, Sarazin M, Legrain S, Dubois B (2006). "Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer's disease: a one-year follow-up study". Clin Neurol Neurosurg. 108 (8): 733–736. doi:10.1016/j.clineuro.2006.02.003. PMID 16567037.CS1 maint: Multiple names: authors list (link)
  32. ↑ Palmer K, Berger AK, Monastero R, Winblad B, Bäckman L, Fratiglioni L (2007). "Predictors of progression from mild cognitive impairment to Alzheimer disease". Neurology. 68 (19): 1596–1602. doi:10.1212/01.wnl.0000260968.92345.3f. PMID 17485646.CS1 maint: Multiple names: authors list (link)
  33. ↑ Small BJ, Gagnon E, Robinson B (2007). "Early identification of cognitive deficits: preclinical Alzheimer's disease and mild cognitive impairment". Geriatrics. 62 (4): 19–23. PMID 17408315. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  34. ↑ Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, และคณะ (January 2004). "Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials". Archives of Neurology. 61 (1): 59–66. doi:10.1001/archneur.61.1.59. PMID 14732621.
  35. 1 2 3 4 5 6 Förstl H, Kurz A (1999). "Clinical features of Alzheimer's disease". European Archives of Psychiatry and Clinical Neuroscience. 249 (6): 288–290. doi:10.1007/s004060050101. PMID 10653284.
  36. ↑ Carlesimo GA, Oscar-Berman M (1992). "Memory deficits in Alzheimer's patients: a comprehensive review". Neuropsychol Rev. 3 (2): 119–69. doi:10.1007/BF01108841. PMID 1300219. Unknown parameter |month= ignored (help)
  37. ↑ Jelicic M, Bonebakker AE, Bonke B (1995). "Implicit memory performance of patients with Alzheimer's disease: a brief review". International Psychogeriatrics. 7 (3): 385–392. doi:10.1017/S1041610295002134. PMID 8821346.CS1 maint: Multiple names: authors list (link)
  38. 1 2 3 Frank EM (1994). "Effect of Alzheimer's disease on communication function". J S C Med Assoc. 90 (9): 417–23. PMID 7967534. Unknown parameter |month= ignored (help)
  39. ↑ Becker JT, Overman AA (2002). "[The semantic memory deficit in Alzheimer's disease]". Rev Neurol (in Spanish; Castilian). 35 (8): 777–83. PMID 12402233.CS1 maint: Unrecognized language (link)
  40. ↑ Hodges JR, Patterson K (1995). "Is semantic memory consistently impaired early in the course of Alzheimer's disease? Neuroanatomical and diagnostic implications". Neuropsychologia. 33 (4): 441–59. doi:10.1016/0028-3932 (94) 00127-B Check |doi= value (help). PMID 7617154. Unknown parameter |month= ignored (help)
  41. ↑ Benke T (1993). "Two forms of apraxia in Alzheimer's disease". Cortex. 29 (4): 715–25. PMID 8124945. Unknown parameter |month= ignored (help)
  42. ↑ Forbes KE, Shanks MF, Venneri A (2004). "The evolution of dysgraphia in Alzheimer's disease". Brain Res. Bull. 63 (1): 19–24. doi:10.1016/j.brainresbull.2003.11.005. PMID 15121235. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  43. ↑ Galasko D, Schmitt F, Thomas R, Jin S, Bennett D (2005). "Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease". Journal of the International Neuropsychology Society. 11 (4): 446–453. PMID 16209425.CS1 maint: Multiple names: authors list (link)
  44. ↑ Galasko D, Schmitt F, Thomas R, Jin S, Bennett D (2005). "Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease". J Int Neuropsychol Soc. 11 (4): 446–53. PMID 16209425. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  45. ↑ Sartori G, Snitz BE, Sorcinelli L, Daum I (2004). "Remote memory in advanced Alzheimer's disease". Arch Clin Neuropsychol. 19 (6): 779–89. doi:10.1016/j.acn.2003.09.007. PMID 15288331. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  46. ↑ Volicer L, Harper DG, Manning BC, Goldstein R, Satlin A (2001). "Sundowning and circadian rhythms in Alzheimer's disease". Am J Psychiatry. 158 (5): 704–11. doi:10.1176/appi.ajp.158.5.704. PMID 11329390. สืบค้นเมื่อ 2008-08-27. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  47. ↑ อาการทางประสาทจิตเวช:
    • Scarmeas N, Brandt J, Blacker D; และคณะ (2007). "Disruptive behavior as a predictor in Alzheimer disease". Arch. Neurol. 64 (12): 1755–61. doi:10.1001/archneur.64.12.1755. PMID 18071039. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
    • Tatsch MF, Bottino CM, Azevedo D; และคณะ (2006). "Neuropsychiatric symptoms in Alzheimer disease and cognitively impaired, nondemented elderly from a community-based sample in Brazil: prevalence and relationship with dementia severity". Am J Geriatr Psychiatry. 14 (5): 438–45. doi:10.1097/01.JGP.0000218218.47279.db. PMID 16670248. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
    • Volicer L, Bass EA, Luther SL (2007). "Agitation and resistiveness to care are two separate behavioral syndromes of dementia". J Am Med Dir Assoc. 8 (8): 527–32. doi:10.1016/j.jamda.2007.05.005. PMID 17931577. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  48. ↑ Honig LS, Mayeux R (2001). "Natural history of Alzheimer's disease". Aging (Milano). 13 (3): 171–82. PMID 11442300. Unknown parameter |month= ignored (help)
  49. ↑ Gold DP, Reis MF, Markiewicz D, Andres D (1995). "When home caregiving ends: a longitudinal study of outcomes for caregivers of relatives with dementia". J Am Geriatr Soc. 43 (1): 10–6. PMID 7806732. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  50. ↑ Bär M, Kruse A, Re S (2003). "[Situations of emotional significance in residents suffering from dementia]". Z Gerontol Geriatr (in German). 36 (6): 454–62. doi:10.1007/s00391-003-0191-0. PMID 14685735. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link) CS1 maint: Unrecognized language (link)
  51. ↑ Souren LE, Franssen EH, Reisberg B (1995). "Contractures and loss of function in patients with Alzheimer's disease". J Am Geriatr Soc. 43 (6): 650–5. PMID 7775724. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  52. ↑ Berkhout AM, Cools HJ, van Houwelingen HC (1998). "The relationship between difficulties in feeding oneself and loss of weight in nursing-home patients with dementia". Age Ageing. 27 (5): 637–41. doi:10.1093/ageing/27.5.637. PMID 12675103. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  53. ↑ Wada H, Nakajoh K, Satoh-Nakagawa T; และคณะ (2001). "Risk factors of aspiration pneumonia in Alzheimer's disease patients". Gerontology. 47 (5): 271–6. doi:10.1159/000052811. PMID 11490146.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
  54. 1 2 Gambassi G, Landi F, Lapane KL, Sgadari A, Mor V, Bernabei R (1999). "Predictors of mortality in patients with Alzheimer's disease living in nursing homes". J. Neurol. Neurosurg. Psychiatr. 67 (1): 59–65. PMC 1736445. PMID 10369823. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  55. ↑ "What We Know Today About Alzheimer's Disease". Alzheimer's Association. Archived from the original on 7 October 2011. สืบค้นเมื่อ 1 October 2011. While scientists know Alzheimer's disease involves progressive brain cell failure, the reason cells fail isn't clear.
  56. ↑ Reitz C, Mayeux R (April 2014). "Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers". Biochemical Pharmacology. 88 (4): 640–51. doi:10.1016/j.bcp.2013.12.024. PMC 3992261. PMID 24398425.
  57. ↑ Wilson RS, Barral S, Lee JH, Leurgans SE, Foroud TM, Sweet RA, Graff-Radford N, Bird TD, Mayeux R, Bennett DA (2011). "Heritability of different forms of memory in the Late Onset Alzheimer's Disease Family Study". Journal of Alzheimer's Disease. 23 (2): 249–55. doi:10.3233/JAD-2010-101515. PMC 3130303. PMID 20930268.
  58. 1 2 3 Blennow K, de Leon MJ, Zetterberg H (July 2006). "Alzheimer's disease". Lancet. 368 (9533): 387–403. doi:10.1016/S0140-6736(06)69113-7. PMID 16876668.
  59. 1 2 Waring SC, Rosenberg RN (March 2008). "Genome-wide association studies in Alzheimer disease". Archives of Neurology. 65 (3): 329–34. doi:10.1001/archneur.65.3.329. PMID 18332245.
  60. ↑ Selkoe DJ (June 1999). "Translating cell biology into therapeutic advances in Alzheimer's disease". Nature. 399 (6738 Suppl): A23–31. doi:10.1038/19866. PMID 10392577.
  61. ↑ Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, และคณะ (November 1996). "Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo". Neuron. 17 (5): 1005–13. doi:10.1016/S0896-6273(00)80230-5. PMID 8938131.
  62. ↑ Kim, JH (December 2018). "Genetics of Alzheimer's Disease". Dementia and Neurocognitive Disorders. 17 (4): 131–36. doi:10.12779/dnd.2018.17.4.131. PMC 6425887. PMID 30906402.
  63. ↑ Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (March 1993). "Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease". Proceedings of the National Academy of Sciences of the United States of America. 90 (5): 1977–81. doi:10.1073/pnas.90.5.1977. PMC 46003. PMID 8446617.
  64. 1 2 Mahley RW, Weisgraber KH, Huang Y (April 2006). "Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease". Proceedings of the National Academy of Sciences of the United States of America. 103 (15): 5644–51. Bibcode:2006PNAS..103.5644M. doi:10.1073/pnas.0600549103. PMC 1414631. PMID 16567625.
  65. ↑ Hall K, Murrell J, Ogunniyi A, Deeg M, Baiyewu O, Gao S, Gureje O, Dickens J, Evans R, Smith-Gamble V, Unverzagt FW, Shen J, Hendrie H (January 2006). "Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba". Neurology. 66 (2): 223–27. doi:10.1212/01.wnl.0000194507.39504.17. PMC 2860622. PMID 16434658.
  66. ↑ Gureje O, Ogunniyi A, Baiyewu O, Price B, Unverzagt FW, Evans RM, และคณะ (January 2006). "APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians". Annals of Neurology. 59 (1): 182–85. doi:10.1002/ana.20694. PMC 2855121. PMID 16278853.
  67. 1 2 Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, และคณะ (December 2013). "Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease". Nature Genetics. 45 (12): 1452–58. doi:10.1038/ng.2802. PMC 3896259. PMID 24162737.
  68. ↑ Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, และคณะ (January 2013). "Variant of TREM2 associated with the risk of Alzheimer's disease". The New England Journal of Medicine (Original article). 368 (2): 107–16. doi:10.1056/NEJMoa1211103. PMC 3677583. PMID 23150908.
  69. ↑ Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, และคณะ (January 2013). "TREM2 variants in Alzheimer's disease". The New England Journal of Medicine (Original article). 368 (2): 117–27. doi:10.1056/NEJMoa1211851. PMC 3631573. PMID 23150934.
  70. ↑ Mukherjee S, Mez J, Trittschuh EH, Saykin AJ, Gibbons LE, Fardo DW, และคณะ (December 2018). "Genetic data and cognitively defined late-onset Alzheimer's disease subgroups". Molecular Psychiatry. doi:10.1038/s41380-018-0298-8. PMC 6548676 Check |pmc= value (help). PMID 30514930.
  71. ↑ Shen ZX (2004). "Brain cholinesterases: II. The molecular and cellular basis of Alzheimer's disease". Med Hypotheses. 63 (2): 308–21. doi:10.1016/j.mehy.2004.02.031. PMID 15236795.
  72. ↑ Hardy J, Allsop D (1991). "Amyloid deposition as the central event in the aetiology of Alzheimer's disease". Trends Pharmacol. Sci. 12 (10): 383–88. doi:10.1016/0165-6147 (91) 90609-V Check |doi= value (help). PMID 1763432. Unknown parameter |month= ignored (help)
  73. 1 2 Mudher A, Lovestone S (2002). "Alzheimer's disease-do tauists and baptists finally shake hands?". Trends Neurosci. 25 (1): 22–26. doi:10.1016/S0166-2236 (00) 02031-2 Check |doi= value (help). PMID 11801334. Unknown parameter |month= ignored (help)
  74. ↑ Nistor M, Don M, Parekh M; และคณะ (2007). "Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain". Neurobiol Aging. 28 (10): 1493–1506. doi:10.1016/j.neurobiolaging.2006.06.023. PMID 16904243. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
  75. ↑ Lott IT, Head E (2005). "Alzheimer disease and Down syndrome: factors in pathogenesis". Neurobiol Aging. 26 (3): 383–89. doi:10.1016/j.neurobiolaging.2004.08.005. PMID 15639317. Unknown parameter |month= ignored (help)
  76. ↑ Polvikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, Niinistö L, Halonen P, Kontula K (November 1995). "Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein". The New England Journal of Medicine. 333 (19): 1242–47. doi:10.1056/NEJM199511093331902. PMID 7566000.
  77. ↑ Transgenic mice:
    • Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F (February 1995). "Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein". Nature. 373 (6514): 523–27. doi:10.1038/373523a0. PMID 7845465.
    • Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D (September 1996). "Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease". The Journal of Neuroscience. 16 (18): 5795–811. doi:10.1523/JNEUROSCI.16-18-05795.1996. PMID 8795633.
    • Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (October 1996). "Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice". Science. 274 (5284): 99–102. doi:10.1126/science.274.5284.99. PMID 8810256.
    • Lalonde R, Dumont M, Staufenbiel M, Sturchler-Pierrat C, Strazielle C (November 2002). "Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation". Brain Research. 956 (1): 36–44. doi:10.1016/S0006-8993(02)03476-5. PMID 12426044.
  78. ↑ Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (February 2009). "Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers". Nature. 457 (7233): 1128–32. doi:10.1038/nature07761. PMC 2748841. PMID 19242475.
  79. 1 2 Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M (February 2009). "APP binds DR6 to trigger axon pruning and neuron death via distinct caspases". Nature. 457 (7232): 981–89. Bibcode:2009Natur.457..981N. doi:10.1038/nature07767. PMC 2677572. PMID 19225519.
  80. ↑ Feuerstein, Adam (14 February 2017). "Merck Alzheimer's Drug Study Halted Early for Futility". New York City: TheStreet, Inc. Archived from the original on 16 February 2017.Merck Alzheimer's Drug Study Halted Early for Futility Independent study monitors concluded that there was "virtually no chance of finding a positive clinical effect."
  81. ↑ "After A Big Failure, Scientists And Patients Hunt For A New Type Of Alzheimer's Drug". NPR.org. สืบค้นเมื่อ 17 May 2019.
  82. ↑ Gallagher, James (2 May 2019). "Dementia is 'greatest health challenge'". สืบค้นเมื่อ 17 May 2019.
  83. ↑ Goedert M, Spillantini MG, Crowther RA (July 1991). "Tau proteins and neurofibrillary degeneration". Brain Pathology. 1 (4): 279–86. doi:10.1111/j.1750-3639.1991.tb00671.x. PMID 1669718.
  84. ↑ Iqbal K, Alonso A, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon S, Li B, Liu F, Rahman A, Tanimukai H, Grundke-Iqbal I (January 2005). "Tau pathology in Alzheimer disease and other tauopathies". Biochimica et Biophysica Acta. 1739 (2–3): 198–210. doi:10.1016/j.bbadis.2004.09.008. PMID 15615638.
  85. ↑ Chun W, Johnson GV (January 2007). "The role of tau phosphorylation and cleavage in neuronal cell death". Frontiers in Bioscience. 12: 733–56. doi:10.2741/2097. PMID 17127334.
  86. ↑ Deane R, Zlokovic BV (April 2007). "Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease". Current Alzheimer Research. 4 (2): 191–97. doi:10.2174/156720507780362245. PMID 17430246.
  87. ↑ Miklossy J (August 2011). "Alzheimer's disease - a neurospirochetosis. Analysis of the evidence following Koch's and Hill's criteria". Journal of Neuroinflammation. 8 (1): 90. doi:10.1186/1742-2094-8-90. PMC 3171359. PMID 21816039.
  88. ↑ Allen, HB (27 June 2016). "Alzheimer's Disease: Assessing the Role of Spirochetes, Biofilms, the Immune System, and Amyloid-β with Regard to Potential Treatment and Prevention". Journal of Alzheimer's Disease. 53 (4): 1271–76. doi:10.3233/JAD-160388. PMC 5008232. PMID 27372648.
  89. ↑ Xu H, Finkelstein DI, Adlard PA (12 June 2014). "Interactions of metals and Apolipoprotein E in Alzheimer's disease". Frontiers in Aging Neuroscience. 6: 121. doi:10.3389/fnagi.2014.00121. PMC 4054654. PMID 24971061. Although we still do not know if the metal ion dyshomeostasis present in AD is a cause or consequence of the disease, there is a growing body of evidence showing a direct correlation between metal ions and key AD-related key proteins.
  90. ↑ Su B, Wang X, Nunomura A, Moreira PI, Lee HG, Perry G, Smith MA, Zhu X (December 2008). "Oxidative stress signaling in Alzheimer's disease". Current Alzheimer Research. 5 (6): 525–32. doi:10.2174/156720508786898451. PMC 2780015. PMID 19075578.
  91. ↑ Kastenholz B, Garfin DE, Horst J, Nagel KA (2009). "Plant metal chaperones: a novel perspective in dementia therapy". Amyloid. 16 (2): 81–83. doi:10.1080/13506120902879392. PMID 20536399.
  92. ↑ "Aluminium and Alzheimer's disease". Facts about dementia. Alzheimer's Society. Archived from the original on 27 October 2005. สืบค้นเมื่อ 14 October 2005.
  93. ↑ Bondy SC (January 2016). "Low levels of aluminum can lead to behavioral and morphological changes associated with Alzheimer's disease and age-related neurodegeneration". Neurotoxicology (Submitted manuscript). 52: 222–29. doi:10.1016/j.neuro.2015.12.002. PMID 26687397.
  94. ↑ Kandimalla R, Vallamkondu J, Corgiat EB, Gill KD (March 2016). "Understanding Aspects of Aluminum Exposure in Alzheimer's Disease Development". Brain Pathology. 26 (2): 139–54. doi:10.1111/bpa.12333. PMID 26494454.
  95. ↑ Santibáñez M, Bolumar F, García AM (November 2007). "Occupational risk factors in Alzheimer's disease: a review assessing the quality of published epidemiological studies". Occupational and Environmental Medicine. 64 (11): 723–32. doi:10.1136/oem.2006.028209. PMC 2078415. PMID 17525096.
  96. 1 2 Lidsky TI (May 2014). "Is the Aluminum Hypothesis dead?". Journal of Occupational and Environmental Medicine. 56 (5 Suppl): S73–79. doi:10.1097/jom.0000000000000063. PMC 4131942. PMID 24806729.
  97. ↑ Yegambaram M, Manivannan B, Beach TG, Halden RU (2015). "Role of environmental contaminants in the etiology of Alzheimer's disease: a review". Current Alzheimer Research. 12 (2): 116–46. doi:10.2174/1567205012666150204121719. PMC 4428475. PMID 25654508.
  98. ↑ Cataldo JK, Prochaska JJ, Glantz SA (2010). "Cigarette smoking is a risk factor for Alzheimer's Disease: an analysis controlling for tobacco industry affiliation". Journal of Alzheimer's Disease. 19 (2): 465–80. doi:10.3233/JAD-2010-1240. PMC 2906761. PMID 20110594.
  99. ↑ Eikelenboom P, van Exel E, Hoozemans JJ, Veerhuis R, Rozemuller AJ, van Gool WA (2010). "Neuroinflammation - an early event in both the history and pathogenesis of Alzheimer's disease". Neuro-Degenerative Diseases. 7 (1–3): 38–41. doi:10.1159/000283480. PMID 20160456.
  100. ↑ Moulton PV, Yang W (2012). "Air pollution, oxidative stress, and Alzheimer's disease". Journal of Environmental and Public Health (Review). 2012: 1–9. doi:10.1155/2012/472751. PMC 3317180. PMID 22523504.
  101. ↑ Bartzokis G (August 2011). "Alzheimer's disease as homeostatic responses to age-related myelin breakdown". Neurobiology of Aging. 32 (8): 1341–71. doi:10.1016/j.neurobiolaging.2009.08.007. PMC 3128664. PMID 19775776.
  102. ↑ Cai Z, Xiao M (2016). "Oligodendrocytes and Alzheimer's disease". The International Journal of Neuroscience. 126 (2): 97–104. doi:10.3109/00207454.2015.1025778. PMID 26000818.
  103. 1 2 3 Reisberg B, Franssen EH, Hasan SM, Monteiro I, Boksay I, Souren LE, และคณะ (1999). "Retrogenesis: clinical, physiologic, and pathologic mechanisms in brain aging, Alzheimer's and other dementing processes". European Archives of Psychiatry and Clinical Neuroscience. 249 Suppl 3 (3): 28–36. doi:10.1007/pl00014170. PMID 10654097.
  104. ↑ Alves GS, Oertel Knöchel V, Knöchel C, Carvalho AF, Pantel J, Engelhardt E, Laks J (2015). "Integrating retrogenesis theory to Alzheimer's disease pathology: insight from DTI-TBSS investigation of the white matter microstructural integrity". BioMed Research International. 2015: 291658. doi:10.1155/2015/291658. PMC 4320890. PMID 25685779.
  105. ↑ Brenner Carson, Verna (2015). Caregiving for Alzheimer's Disease. New York: Springer New York Academy of Sciences. pp. 1–9. ISBN 978-1-4939-2406-6.
  106. ↑ Wenk GL (2003). "Neuropathologic changes in Alzheimer's disease". The Journal of Clinical Psychiatry. 64 Suppl 9: 7–10. PMID 12934968.
  107. ↑ Braak H, Del Tredici K (December 2012). "Where, when, and in what form does sporadic Alzheimer's disease begin?". Current Opinion in Neurology. 25 (6): 708–14. doi:10.1097/WCO.0b013e32835a3432. PMID 23160422.
  108. ↑ Desikan RS, Cabral HJ, Hess CP, Dillon WP, Glastonbury CM, Weiner MW, Schmansky NJ, Greve DN, Salat DH, Buckner RL, Fischl B (August 2009). "Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease". Brain. 132 (Pt 8): 2048–57. doi:10.1093/brain/awp123. PMC 2714061. PMID 19460794.
  109. ↑ Moan R (20 July 2009). "MRI Software Accurately IDs Preclinical Alzheimer's Disease". Diagnostic Imaging. Archived from the original on 16 May 2016. สืบค้นเมื่อ 7 January 2013.
  110. 1 2 Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J (2004). "The importance of neuritic plaques and tangles to the development and evolution of AD". Neurology. 62 (11): 1984–9. PMID 15184601. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  111. ↑ Bouras C, Hof PR, Giannakopoulos P, Michel JP, Morrison JH (1994). "Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital". Cereb. Cortex. 4 (2): 138–50. doi:10.1093/cercor/4.2.138. PMID 8038565.CS1 maint: Multiple names: authors list (link)
  112. ↑ Kotzbauer PT, Trojanowsk JQ, Lee VM (October 2001). "Lewy body pathology in Alzheimer's disease". Journal of Molecular Neuroscience. 17 (2): 225–32. doi:10.1385/JMN:17:2:225. PMID 11816795.
  113. ↑ Hashimoto M, Rockenstein E, Crews L, Masliah E (2003). "Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases". Neuromolecular Med. 4 (1–2): 21–36. doi:10.1385/NMM:4:1-2:21. PMID 14528050.CS1 maint: Multiple names: authors list (link)
  114. ↑ Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J (2006). "Synapse formation and function is modulated by the amyloid precursor protein". J. Neurosci. 26 (27): 7212–21. doi:10.1523/JNEUROSCI.1450-06.2006. PMID 16822978. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  115. ↑ Turner PR, O'Connor K, Tate WP, Abraham WC (2003). "Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory". Prog. Neurobiol. 70 (1): 1–32. doi:10.1016/S0301-0082 (03) 00089-3 Check |doi= value (help). PMID 12927332. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  116. ↑ Hooper NM (2005). "Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein". Biochem. Soc. Trans. 33 (Pt 2): 335–8. doi:10.1042/BST0330335. PMID 15787600. Unknown parameter |month= ignored (help)
  117. ↑ Ohnishi S, Takano K (2004). "Amyloid fibrils from the viewpoint of protein folding". Cell. Mol. Life Sci. 61 (5): 511–24. doi:10.1007/s00018-003-3264-8. PMID 15004691. Unknown parameter |month= ignored (help)
  118. ↑ Hernández F, Avila J (2007). "Tauopathies". Cell. Mol. Life Sci. 64 (17): 2219–33. doi:10.1007/s00018-007-7220-x. PMID 17604998. Unknown parameter |month= ignored (help)
  119. ↑ Sun W, Samimi H, Gamez M, Zare H, Frost B (August 2018). "Pathogenic tau-induced piRNA depletion promotes neuronal death through transposable element dysregulation in neurodegenerative tauopathies". Nature Neuroscience. 21 (8): 1038–48. doi:10.1038/s41593-018-0194-1. PMC 6095477. PMID 30038280.
  120. ↑ Van Broeck B, Van Broeckhoven C, Kumar-Singh S (2007). "Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic approaches". Neurodegener Dis. 4 (5): 349–65. doi:10.1159/000105156. PMID 17622778.CS1 maint: Multiple names: authors list (link)
  121. ↑ Yankner BA, Duffy LK, Kirschner DA (1990). "Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides". Science (journal). 250 (4978): 279–82. doi:10.1126/science.2218531. PMID 2218531. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  122. ↑ Chen X, Yan SD (2006). "Mitochondrial Abeta: a potential cause of metabolic dysfunction in Alzheimer's disease". IUBMB Life. 58 (12): 686–94. doi:10.1080/15216540601047767. PMID 17424907. Unknown parameter |month= ignored (help)
  123. ↑ Greig NH, Mattson MP, Perry T; และคณะ (2004). "New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists". Ann. N. Y. Acad. Sci. 1035: 290–315. doi:10.1196/annals.1332.018. PMID 15681814. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
  124. ↑ Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, และคณะ (April 2015). "Neuroinflammation in Alzheimer's disease". The Lancet. Neurology. 14 (4): 388–405. doi:10.1016/S1474-4422(15)70016-5. PMC 5909703. PMID 25792098.
  125. ↑ Tapia-Arancibia L, Aliaga E, Silhol M, Arancibia S (November 2008). "New insights into brain BDNF function in normal aging and Alzheimer disease". Brain Research Reviews. 59 (1): 201–20. doi:10.1016/j.brainresrev.2008.07.007. PMID 18708092.
  126. ↑ Schindowski K, Belarbi K, Buée L (February 2008). "Neurotrophic factors in Alzheimer's disease: role of axonal transport". Genes, Brain, and Behavior. 7 (Suppl 1): 43–56. doi:10.1111/j.1601-183X.2007.00378.x. PMC 2228393. PMID 18184369.
  127. ↑ Mendez MF (2006). "The accurate diagnosis of early-onset dementia". International Journal of Psychiatry Medicine. 36 (4): 401–412. doi:10.2190/Q6J4-R143-P630-KW41. PMID 17407994.
  128. ↑ Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J (2006). "Therapeutic approaches to Alzheimer's disease". Brain. 129 (Pt 11): 2840–55. doi:10.1093/brain/awl280. PMID 17018549. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  129. ↑ "Dementia: Quick reference guide" (PDF). London: (UK) National Institute for Health and Clinical Excellence. 2006. ISBN 1-84629-312-X. สืบค้นเมื่อ 2008-02-22. Unknown parameter |month= ignored (help)
  130. ↑ Schroeter ML, Stein T, Maslowski N, Neumann J (October 2009). "Neural correlates of Alzheimer's disease and mild cognitive impairment: a systematic and quantitative meta-analysis involving 1351 patients". NeuroImage. 47 (4): 1196–206. doi:10.1016/j.neuroimage.2009.05.037. PMC 2730171. PMID 19463961.
  131. 1 2 McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984). "Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease". Neurology. 34 (7): 939–44. PMID 6610841. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  132. 1 2 Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, และคณะ (August 2007). "Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria". The Lancet. Neurology. 6 (8): 734–46. doi:10.1016/S1474-4422(07)70178-3. PMID 17616482.
  133. ↑ Blacker D, Albert MS, Bassett SS, Go RC, Harrell LE, Folstein MF (1994). "Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease. The National Institute of Mental Health Genetics Initiative". Arch. Neurol. 51 (12): 1198–204. PMID 7986174. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  134. ↑ American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders: DSM-IV-TR (4th Edition Text Revision ed.). Washington DC: American Psychiatric Association. ISBN 0890420254.
  135. ↑ Ito N (1996). "[Clinical aspects of dementia]". Hokkaido Igaku Zasshi (in Japanese). 71 (3): 315–20. PMID 8752526. Unknown parameter |month= ignored (help)CS1 maint: Unrecognized language (link)
  136. ↑ Tombaugh TN, McIntyre NJ (1992). "The mini-mental state examination: a comprehensive review". J Am Geriatr Soc. 40 (9): 922–35. PMID 1512391. Unknown parameter |month= ignored (help)
  137. ↑ Pasquier F (1999). "Early diagnosis of dementia: neuropsychology". J. Neurol. 246 (1): 6–15. doi:10.1007/s004150050299. PMID 9987708. Unknown parameter |month= ignored (help)
  138. ↑ Harvey PD, Moriarty PJ, Kleinman L; และคณะ (2005). "The validation of a caregiver assessment of dementia: the Dementia Severity Scale". Alzheimer Dis Assoc Disord. 19 (4): 186–94. doi:10.1097/01.wad.0000189034.43203.60. PMID 16327345.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
  139. ↑ Antoine C, Antoine P, Guermonprez P, Frigard B (2004). "[Awareness of deficits and anosognosia in Alzheimer's disease.]". Encephale (in French). 30 (6): 570–7. PMID 15738860.CS1 maint: Multiple names: authors list (link) CS1 maint: Unrecognized language (link)
  140. ↑ Cruz VT, Pais J, Teixeira A, Nunes B (2004). "[The initial symptoms of Alzheimer disease: caregiver perception]". Acta Med Port (in Portuguese). 17 (6): 435–44. PMID 16197855.CS1 maint: Multiple names: authors list (link) CS1 maint: Unrecognized language (link)
  141. ↑ Clarfield AM (2003). "The decreasing prevalence of reversible dementias: an updated meta-analysis". Arch. Intern. Med. 163 (18): 2219–29. doi:10.1001/archinte.163.18.2219. PMID 14557220. Unknown parameter |month= ignored (help)
  142. ↑ Geldmacher DS, Whitehouse PJ (1997). "Differential diagnosis of Alzheimer's disease". Neurology. 48 (5 Suppl 6): S2–9. PMID 9153154. Unknown parameter |month= ignored (help)
  143. ↑ Potter GG, Steffens DC (2007). "Contribution of depression to cognitive impairment and dementia in older adults". Neurologist. 13 (3): 105–17. doi:10.1097/01.nrl.0000252947.15389.a9. PMID 17495754. Unknown parameter |month= ignored (help)
  144. ↑ Zhang S, Smailagic N, Hyde C, Noel-Storr AH, Takwoingi Y, McShane R, Feng J (July 2014). "(11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)". The Cochrane Database of Systematic Reviews (7): CD010386. doi:10.1002/14651858.CD010386.pub2. PMC 6464750. PMID 25052054.
  145. ↑ Smailagic N, Vacante M, Hyde C, Martin S, Ukoumunne O, Sachpekidis C (January 2015). "¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)". The Cochrane Database of Systematic Reviews. 1: CD010632. doi:10.1002/14651858.CD010632.pub2. PMID 25629415.
  146. 1 2 Hu N, Yu JT, Tan L, Wang YL, Sun L, Tan L (2013). "Nutrition and the risk of Alzheimer's disease". BioMed Research International (Review). 2013: 1–12. doi:10.1155/2013/524820. PMC 3705810. PMID 23865055.
  147. ↑ Solfrizzi V, Panza F, Frisardi V, Seripa D, Logroscino G, Imbimbo BP, Pilotto A (May 2011). "Diet and Alzheimer's disease risk factors or prevention: the current evidence". Expert Review of Neurotherapeutics. 11 (5): 677–708. doi:10.1586/ern.11.56. PMID 21539488.
  148. ↑ Kanoski SE, Davidson TL (April 2011). "Western diet consumption and cognitive impairment: links to hippocampal dysfunction and obesity". Physiology & Behavior (Review). 103 (1): 59–68. doi:10.1016/j.physbeh.2010.12.003. PMC 3056912. PMID 21167850.
  149. ↑ Solfrizzi V, Capurso C, D'Introno A, Colacicco AM, Santamato A, Ranieri M, Fiore P, Capurso A, Panza F (January 2008). "Lifestyle-related factors in predementia and dementia syndromes". Expert Review of Neurotherapeutics. 8 (1): 133–58. doi:10.1586/14737175.8.1.133. PMID 18088206.
  150. ↑ Santos C, Costa J, Santos J, Vaz-Carneiro A, Lunet N (2010). "Caffeine intake and dementia: systematic review and meta-analysis". Journal of Alzheimer's Disease. 20 Suppl 1: S187–204. doi:10.3233/JAD-2010-091387. PMID 20182026.
  151. ↑ Nehlig A (March 2013). "The neuroprotective effects of cocoa flavanol and its influence on cognitive performance". British Journal of Clinical Pharmacology (Review). 75 (3): 716–27. doi:10.1111/j.1365-2125.2012.04378.x. PMC 3575938. PMID 22775434.
  152. ↑ Stoclet JC, Schini-Kerth V (March 2011). "[Dietary flavonoids and human health]". Annales Pharmaceutiques Francaises. 69 (2): 78–90. doi:10.1016/j.pharma.2010.11.004. PMID 21440100.
  153. ↑ Ono K, Yamada M (April 2012). "Vitamin A and Alzheimer's disease". Geriatrics & Gerontology International (Review). 12 (2): 180–88. doi:10.1111/j.1447-0594.2011.00786.x. PMID 22221326.
  154. ↑ Lerner AJ, Gustaw-Rothenberg K, Smyth S, Casadesus G (March–April 2012). "Retinoids for treatment of Alzheimer's disease". BioFactors. 38 (2): 84–89. doi:10.1002/biof.196. PMID 22419567.
  155. ↑ Heo JH, Lee KM (March 2013). "The possible role of antioxidant vitamin C in Alzheimer's disease treatment and prevention". American Journal of Alzheimer's Disease and Other Dementias (Review). 28 (2): 120–25. doi:10.1177/1533317512473193. PMID 23307795.
  156. ↑ Boothby LA, Doering PL (December 2005). "Vitamin C and vitamin E for Alzheimer's disease". The Annals of Pharmacotherapy. 39 (12): 2073–80. doi:10.1345/aph.1E495. PMID 16227450.
  157. 1 2 Farina N, Llewellyn D, Isaac MG, Tabet N (April 2017). "Vitamin E for Alzheimer's dementia and mild cognitive impairment". The Cochrane Database of Systematic Reviews. 4: CD002854. doi:10.1002/14651858.CD002854.pub5. PMC 6478142. PMID 28418065.
  158. ↑ Loef M, Schrauzer GN, Walach H (2011). "Selenium and Alzheimer's disease: a systematic review". Journal of Alzheimer's Disease (Review). 26 (1): 81–104. doi:10.3233/JAD-2011-110414. PMID 21593562.
  159. ↑ Loef M, von Stillfried N, Walach H (September 2012). "Zinc diet and Alzheimer's disease: a systematic review". Nutritional Neuroscience (Review). 15 (5): 2–12. doi:10.1179/1476830512Y.0000000010. PMID 22583839.
  160. ↑ Avan A, Hoogenraad TU (2015). "Zinc and Copper in Alzheimer's Disease". Journal of Alzheimer's Disease (Review). 46 (1): 89–92. doi:10.3233/JAD-150186. PMID 25835420.
  161. ↑ Malouf R, Grimley Evans J (October 2008). "Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people". The Cochrane Database of Systematic Reviews (4): CD004514. doi:10.1002/14651858.CD004514.pub2. PMID 18843658.
  162. ↑ Wald DS, Kasturiratne A, Simmonds M (June 2010). "Effect of folic acid, with or without other B vitamins, on cognitive decline: meta-analysis of randomized trials". The American Journal of Medicine. 123 (6): 522–527.e2. doi:10.1016/j.amjmed.2010.01.017. PMID 20569758.
  163. ↑ Cunnane SC, Chouinard-Watkins R, Castellano CA, Barberger-Gateau P (January 2013). "Docosahexaenoic acid homeostasis, brain aging and Alzheimer's disease: Can we reconcile the evidence?". Prostaglandins, Leukotrienes, and Essential Fatty Acids. 88 (1): 61–70. doi:10.1016/j.plefa.2012.04.006. PMID 22575581.
  164. ↑ Burckhardt M, Herke M, Wustmann T, Watzke S, Langer G, Fink A (April 2016). "Omega-3 fatty acids for the treatment of dementia". The Cochrane Database of Systematic Reviews. 4: CD009002. doi:10.1002/14651858.CD009002.pub3. PMID 27063583.
  165. ↑ เคอร์คิวมินในอาหาร:
    • Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ (2007). "Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model". Journal of Neurochemistry. 102 (4): 1095–1104. doi:10.1111/j.1471-4159.2007.04613.x. PMID 17472706.CS1 maint: Multiple names: authors list (link)
    • Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM (2001). "The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse". Journal of Neuroscience. 21 (21): 8370–8377. PMID 11606625.CS1 maint: Multiple names: authors list (link)
  166. ↑ Birks J, Grimley Evans J (2007). "Ginkgo biloba for cognitive impairment and dementia". Cochrane Database Syst Rev (2): CD003120. doi:10.1002/14651858.CD003120.pub2. PMID 17443523. สืบค้นเมื่อ 2008-02-22.
  167. ↑ Krishnan S, Cairns R, Howard R (April 2009). Krishnan S, ed. "Cannabinoids for the treatment of dementia". The Cochrane Database of Systematic Reviews (2): CD007204. doi:10.1002/14651858.CD007204.pub2. PMID 19370677.
  168. ↑ Bilkei-Gorzo A (December 2012). "The endocannabinoid system in normal and pathological brain ageing". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 367 (1607): 3326–41. doi:10.1098/rstb.2011.0388. PMC 3481530. PMID 23108550.
  169. ↑ Rosendorff C, Beeri MS, Silverman JM (2007). "Cardiovascular risk factors for Alzheimer's disease". Am J Geriatr Cardiol. 16 (3): 143–9. doi:10.1111/j.1076-7460.2007.06696.x. PMID 17483665.CS1 maint: Multiple names: authors list (link)
  170. ↑ Patterson C, Feightner JW, Garcia A, Hsiung GY, MacKnight C, Sadovnick AD (2008). "Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease". CMAJ. 178 (5): 548–56. doi:10.1503/cmaj.070796. PMC 2244657. PMID 18299540. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  171. ↑ Reiss AB, Wirkowski E (2007). "Role of HMG-CoA reductase inhibitors in neurological disorders : progress to date". Drugs. 67 (15): 2111–20. doi:10.2165/00003495-200767150-00001. PMID 17927279.
  172. ↑ Kuller LH (2007). "Statins and dementia". Curr Atheroscler Rep. 9 (2): 154–61. doi:10.1007/s11883-007-0012-9. PMID 17877925. Unknown parameter |month= ignored (help)
  173. ↑ Szekely CA, Breitner JC, Fitzpatrick AL; และคณะ (2008). "NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type". Neurology. 70 (1): 17–24. doi:10.1212/01.wnl.0000284596.95156.48. PMID 18003940. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
  174. ↑ Hoozemans JJ, Veerhuis R, Rozemuller JM, Eikelenboom P (February 2011). "Soothing the inflamed brain: effect of non-steroidal anti-inflammatory drugs on Alzheimer's disease pathology". CNS & Neurological Disorders Drug Targets. 10 (1): 57–67. doi:10.2174/187152711794488665. PMID 21143138.
  175. ↑ Craig MC, Murphy DG (2007). "Estrogen: effects on normal brain function and neuropsychiatric disorders". Climacteric. 10 Suppl 2: 97–104. doi:10.1080/13697130701598746. PMID 17882683. Unknown parameter |month= ignored (help)
  176. ↑ Mori K, Takeda M (2007). "[Hormone replacement Up-to-date. Hormone replacement therapy and brain function]". Clin Calcium (in Japanese). 17 (9): 1349–54. PMID 17767023. Unknown parameter |month= ignored (help)CS1 maint: Unrecognized language (link)
  177. ↑ Verghese J, Lipton RB, Katz MJ; และคณะ (2003). "Leisure activities and the risk of dementia in the elderly". N. Engl. J. Med. 348 (25): 2508–16. doi:10.1056/NEJMoa022252. PMID 12815136. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
  178. ↑ Bennett DA, Schneider JA, Tang Y, Arnold SE, Wilson RS (2006). "The effect of social networks on the relation between Alzheimer's disease pathology and level of cognitive function in old people: a longitudinal cohort study". Lancet Neurol. 5 (5): 406–412. doi:10.1016/S1474-4422 (06) 70417-3 Check |doi= value (help). PMID 16632311.CS1 maint: Multiple names: authors list (link)
  179. 1 2 Paradise M, Cooper C, Livingston G (February 2009). "Systematic review of the effect of education on survival in Alzheimer's disease". International Psychogeriatrics. 21 (1): 25–32. doi:10.1017/S1041610208008053. PMID 19026089.
  180. ↑ Bialystok E, Craik FIM, Freedman M (2007). "Bilingualism as a protection against the onset of symptoms of dementia". Neuropsychologia. 42 (2): 459–464. doi:10.1016/j.neuropsychologia.2006.10.009.CS1 maint: Multiple names: authors list (link)
  181. ↑ Cheng ST (September 2016). "Cognitive Reserve and the Prevention of Dementia: the Role of Physical and Cognitive Activities". Current Psychiatry Reports. 18 (9): 85. doi:10.1007/s11920-016-0721-2. PMC 4969323. PMID 27481112.
  182. ↑ Farina N, Rusted J, Tabet N (January 2014). "The effect of exercise interventions on cognitive outcome in Alzheimer's disease: a systematic review". International Psychogeriatrics. 26 (1): 9–18. doi:10.1017/S1041610213001385. PMID 23962667.
  183. 1 2 3 Birks JS, Harvey RJ (June 2018). "Donepezil for dementia due to Alzheimer's disease". The Cochrane Database of Systematic Reviews. 6: CD001190. doi:10.1002/14651858.CD001190.pub3. PMC 6513124 Check |pmc= value (help). PMID 29923184.
  184. 1 2 Birks JS, Grimley Evans J (April 2015). "Rivastigmine for Alzheimer's disease". The Cochrane Database of Systematic Reviews (4): CD001191. doi:10.1002/14651858.CD001191.pub3. PMID 25858345.
  185. ↑ Geula C, Mesulam MM (1995). "Cholinesterases and the pathology of Alzheimer disease". Alzheimer Dis Assoc Disord. 9 Suppl 2: 23–28. PMID 8534419.
  186. ↑ Stahl SM (2000). "The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action". J Clin Psychiatry. 61 (11): 813–814. PMID 11105732.
  187. 1 2 Birks J (January 2006). Birks J, ed. "Cholinesterase inhibitors for Alzheimer's disease". The Cochrane Database of Systematic Reviews (1): CD005593. doi:10.1002/14651858.CD005593. PMID 16437532.
  188. ↑ Raschetti R, Albanese E, Vanacore N, Maggini M (November 2007). "Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials". PLoS Medicine. 4 (11): e338. doi:10.1371/journal.pmed.0040338. PMC 2082649. PMID 18044984.
  189. ↑ Alldredge BK, Corelli RL, Ernst ME, Guglielmo BJ, Jacobson PA, Kradjan WA, Williams BR (2013). Applied therapeutics : the clinical use of drugs (10th ed.). Baltimore: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 2385. ISBN 978-1-60913-713-7.
  190. 1 2 Lipton SA (2006). "Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond". Nat Rev Drug Discov. 5 (2): 160–170. doi:10.1038/nrd1958. PMID 16424917.
  191. ↑ "Memantine". US National Library of Medicine (Medline). 2004-01-04. สืบค้นเมื่อ 2008-03-22.
  192. ↑ Areosa Sastre A, McShane R, Sherriff F (2004). "Memantine for dementia". Cochrane Database Syst Rev (4): CD003154. doi:10.1002/14651858.CD003154.pub2. PMID 15495043.CS1 maint: Multiple names: authors list (link)
  193. ↑ "Namenda Prescribing Information" (PDF). Forest Pharmaceuticals. สืบค้นเมื่อ 2008-02-19.
  194. ↑ Raina P, Santaguida P, Ismaila A; และคณะ (2008). "Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline". Annals of Internal Medicine. 148 (5): 379–397. PMID 18316756.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
  195. ↑ การใช้ยาระงับอาการทางจิต:
    • Ballard C, Waite J (2006). "The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease". Cochrane Database Syst Rev (1): CD003476. doi:10.1002/14651858.CD003476.pub2. PMID 16437455.
    • Ballard C, Lana MM, Theodoulou M; และคณะ (2008). "A Randomised, Blinded, Placebo-Controlled Trial in Dementia Patients Continuing or Stopping Neuroleptics (The DART-AD Trial)". PLoS Med. 5 (4): e76. doi:10.1371/journal.pmed.0050076. PMID 18384230.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
    • Sink KM, Holden KF, Yaffe K (2005). "Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence". JAMA. 293 (5): 596–608. doi:10.1001/jama.293.5.596. PMID 15687315.CS1 maint: Multiple names: authors list (link)
  196. 1 2 Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, Gill R, Juszczak E, Yu L-M, Jacoby R (9 January 2009). "The dementia antipsychotic withdrawal trial (DART-AD) : long-term follow-up of a randomised placebo-controlled trial". Lancet Neurology. 8: 151. doi:10.1016/S1474-4422 (08) 70295-3 Check |doi= value (help). PMID 19138567. Lay summary.CS1 maint: Multiple names: authors list (link)
  197. ↑ Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AI, van Driel ML, Christiaens T (March 2013). "Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia". The Cochrane Database of Systematic Reviews. 3 (3): CD007726. doi:10.1002/14651858.CD007726.pub2. hdl:1854/LU-3109108. PMID 23543555.
  198. ↑ Li J, Wu HM, Zhou RL, Liu GJ, Dong BR (April 2008). "Huperzine A for Alzheimer's disease". The Cochrane Database of Systematic Reviews (2): CD005592. doi:10.1002/14651858.CD005592.pub2. PMID 18425924.
  199. 1 2 3 4 5 6 7 "Practice Guideline for the Treatment of Patients with Alzheimer's disease and Other Dementias" (PDF). American Psychiatric Association. 2007. doi:10.1176/appi.books.9780890423967.152139. สืบค้นเมื่อ 2007-12-28. Unknown parameter |month= ignored (help)
  200. ↑ Bottino CM, Carvalho IA, Alvarez AM; และคณะ (2005). "Cognitive rehabilitation combined with drug treatment in Alzheimer's disease patients: a pilot study". Clin Rehabil. 19 (8): 861–869. doi:10.1191/0269215505cr911oa. PMID 16323385.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
  201. ↑ Doody RS, Stevens JC, Beck C; และคณะ (2001). "Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology". Neurology. 56 (9): 1154–1166. PMID 11342679.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
  202. ↑ Hermans DG, Htay UH, McShane R (2007). "Non-pharmacological interventions for wandering of people with dementia in the domestic setting". Cochrane Database Syst Rev (1): CD005994. doi:10.1002/14651858.CD005994.pub2. PMID 17253573.CS1 maint: Multiple names: authors list (link)
  203. ↑ Robinson L, Hutchings D, Dickinson HO; และคณะ (2007). "Effectiveness and acceptability of non-pharmacological interventions to reduce wandering in dementia: a systematic review". Int J Geriatr Psychiatry. 22 (1): 9–22. doi:10.1002/gps.1643. PMID 17096455.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
  204. ↑ Abraha I, Rimland JM, Trotta FM, Dell'Aquila G, Cruz-Jentoft A, Petrovic M, Gudmundsson A, Soiza R, O'Mahony D, Guaita A, Cherubini A (March 2017). "Systematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-OnTop series". BMJ Open. 7 (3): e012759. doi:10.1136/bmjopen-2016-012759. PMC 5372076. PMID 28302633.
  205. ↑ Chung JC, Lai CK, Chung PM, French HP (2002). "Snoezelen for dementia". The Cochrane Database of Systematic Reviews (4): CD003152. doi:10.1002/14651858.CD003152. PMID 12519587.
  206. ↑ Woods B, O'Philbin L, Farrell EM, Spector AE, Orrell M (March 2018). "Reminiscence therapy for dementia". The Cochrane Database of Systematic Reviews. 3: CD001120. doi:10.1002/14651858.CD001120.pub3. PMC 6494367. PMID 29493789.
  207. ↑ Peak JS, Cheston RI (2002). "Using simulated presence therapy with people with dementia". Aging Ment Health. 6 (1): 77–81. doi:10.1080/13607860120101095. PMID 11827626.
  208. ↑ Camberg L, Woods P, Ooi WL; และคณะ (1999). "Evaluation of Simulated Presence: a personalised approach to enhance well-being in persons with Alzheimer's disease". J Am Geriatr Soc. 47 (4): 446–452. PMID 10203120.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
  209. ↑ Neal M, Briggs M (2003). "Validation therapy for dementia". Cochrane Database Syst Rev (3): CD001394. doi:10.1002/14651858.CD001394. PMID 12917907.
  210. ↑ Chung JC, Lai CK, Chung PM, French HP (2002). "Snoezelen for dementia". Cochrane Database Syst Rev (4): CD003152. doi:10.1002/14651858.CD003152. PMID 12519587.CS1 maint: Multiple names: authors list (link)
  211. ↑ Spector A, Orrell M, Davies S, Woods B (2000). "Withdrawn: Reality orientation for dementia". Cochrane Database Syst Rev (3): CD001119. doi:10.1002/14651858.CD001119.pub2. PMID 17636652.CS1 maint: Multiple names: authors list (link)
  212. ↑ Spector A, Thorgrimsen L, Woods B; และคณะ (2003). "Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial". Br J Psychiatry. 183: 248–254. doi:10.1192/bjp.183.3.248. PMID 12948999.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
  213. ↑ Chang CH, Lane HY, Lin CH (2018). "Brain Stimulation in Alzheimer's Disease". Frontiers in Psychiatry. 9: 201. doi:10.3389/fpsyt.2018.00201. PMC 5992378. PMID 29910746.แม่แบบ:CC-notice
  214. ↑ Gitlin LN, Corcoran M, Winter L, Boyce A, Hauck WW (2001). "A randomized, controlled trial of a home environmental intervention: effect on efficacy and upset in caregivers and on daily function of persons with dementia". Gerontologist. 41 (1): 4–14. PMID 11220813. สืบค้นเมื่อ 2008-07-15. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  215. ↑ Gitlin LN, Hauck WW, Dennis MP, Winter L (2005). "Maintenance of effects of the home environmental skill-building program for family caregivers and individuals with Alzheimer's disease and related disorders". J. Gerontol. A Biol. Sci. Med. Sci. 60 (3): 368–74. PMID 15860476. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  216. ↑ "Treating behavioral and psychiatric symptoms". Alzheimer's Association. 2006. สืบค้นเมื่อ 2006-09-25.
  217. ↑ Dunne TE, Neargarder SA, Cipolloni PB, Cronin-Golomb A (2004). "Visual contrast enhances food and liquid intake in advanced Alzheimer's disease". Clinical Nutrition. 23 (4): 533–538. doi:10.1016/j.clnu.2003.09.015. PMID 15297089.CS1 maint: Multiple names: authors list (link)
  218. ↑ Dudek, Susan G. (2007). Nutrition essentials for nursing practice. Hagerstown, Maryland: Lippincott Williams & Wilkins. p. 360. ISBN 0-7817-6651-6. สืบค้นเมื่อ 2008-08-19.
  219. ↑ Dennehy C (2006). "Analysis of patients' rights: dementia and PEG insertion". Br J Nurs. 15 (1): 18–20. PMID 16415742.
  220. ↑ Chernoff R (2006). "Tube feeding patients with dementia". Nutr Clin Pract. 21 (2): 142–6. doi:10.1177/0115426506021002142. PMID 16556924. Unknown parameter |month= ignored (help)
  221. ↑ ปัญหาทางการแพทย์:
    • Head B (2003). "Palliative care for persons with dementia". Home Healthc Nurse. 21 (1): 53–60, quiz 61. doi:10.1097/00004045-200301000-00012. PMID 12544465. Unknown parameter |month= ignored (help)
    • Friedlander AH, Norman DC, Mahler ME, Norman KM, Yagiela JA (2006). "Alzheimer's disease: psychopathology, medical management and dental implications". J Am Dent Assoc. 137 (9): 1240–51. PMID 16946428. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
    • Belmin J (2007). "Practical guidelines for the diagnosis and management of weight loss in Alzheimer's disease: a consensus from appropriateness ratings of a large expert panel". J Nutr Health Aging. 11 (1): 33–7. PMID 17315078.
    • McCurry SM, Gibbons LE, Logsdon RG, Vitiello M, Teri L (2003). "Training caregivers to change the sleep hygiene practices of patients with dementia: the NITE-AD project". J Am Geriatr Soc. 51 (10): 1455–60. doi:10.1046/j.1532-5415.2003.51466.x. PMID 14511168. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
    • Perls TT, Herget M (1995). "Higher respiratory infection rates on an Alzheimer's special care unit and successful intervention". J Am Geriatr Soc. 43 (12): 1341–4. PMID 7490383. Unknown parameter |month= ignored (help)
  222. ↑ Shega JW, Levin A, Hougham GW; และคณะ (2003). "Palliative Excellence in Alzheimer Care Efforts (PEACE) : a program description". J Palliat Med. 6 (2): 315–20. doi:10.1089/109662103764978641. PMID 12854952. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
  223. 1 2 Zanetti O, Solerte SB, Cantoni F (2009). "Life expectancy in Alzheimer's disease (AD)". Archives of Gerontology and Geriatrics. 49 Suppl 1: 237–43. doi:10.1016/j.archger.2009.09.035. PMID 19836639.
  224. 1 2 Mölsä PK, Marttila RJ, Rinne UK (March 1995). "Long-term survival and predictors of mortality in Alzheimer's disease and multi-infarct dementia". Acta Neurologica Scandinavica. 91 (3): 159–64. doi:10.1111/j.1600-0404.1995.tb00426.x. PMID 7793228.
  225. ↑ Larson EB, Shadlen MF, Wang L; และคณะ (2004). "Survival after initial diagnosis of Alzheimer disease". Ann. Intern. Med. 140 (7): 501–9. PMID 15068977. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
  226. ↑ Jagger C, Clarke M, Stone A (1995). "Predictors of survival with Alzheimer's disease: a community-based study". Psychol Med. 25 (1): 171–7. PMID 7792352. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  227. ↑ Dodge HH, Shen C, Pandav R, DeKosky ST, Ganguli M (February 2003). "Functional transitions and active life expectancy associated with Alzheimer disease". Archives of Neurology. 60 (2): 253–59. doi:10.1001/archneur.60.2.253. PMID 12580712.
  228. 1 2 Ganguli M, Dodge HH, Shen C, Pandav RS, DeKosky ST (2005). "Alzheimer disease and mortality: a 15-year epidemiological study". Arch. Neurol. 62 (5): 779–84. doi:10.1001/archneur.62.5.779. PMID 15883266. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  229. 1 2 3 Bermejo-Pareja F, Benito-León J, Vega S, Medrano MJ, Román GC (2008). "Incidence and subtypes of dementia in three elderly populations of central Spain". J. Neurol. Sci. 264 (1–2): 63–72. doi:10.1016/j.jns.2007.07.021. PMID 17727890. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  230. 1 2 3 Di Carlo A, Baldereschi M, Amaducci L; และคณะ (2002). "Incidence of dementia, Alzheimer's disease, and vascular dementia in Italy. The ILSA Study". J Am Geriatr Soc. 50 (1): 41–8. doi:10.1046/j.1532-5415.2002.50006.x. PMID 12028245. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
  231. ↑ Andersen K, Launer LJ, Dewey ME; และคณะ (1999). "Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group". Neurology. 53 (9): 1992–7. PMID 10599770. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
  232. ↑ Tejada-Vera B. (2013). Mortality from Alzheimer's Disease in the United States: Data for 2000 and 2010. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics.
  233. ↑ การประมาณในสหรัฐ ค.ศ. 2000:
  234. 1 2 Ferri CP, Prince M, Brayne C; และคณะ (2005). "Global prevalence of dementia: a Delphi consensus study" (PDF). Lancet. 366 (9503): 2112–7. doi:10.1016/S0140-6736 (05) 67889-0 Check |doi= value (help). PMID 16360788. สืบค้นเมื่อ 2008-06-13. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
  235. ↑ World Health Organization (2006). Neurological Disorders: Public Health Challenges. Switzerland: World Health Organization. pp. 204–207. ISBN 978-92-4-156336-9.
  236. ↑ 2006 prevalence estimate:
  237. 1 2 Berchtold NC, Cotman CW (1998). "Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s". Neurobiology of Aging. 19 (3): 173–189. doi:10.1016/S0197-4580 (98) 00052-9 Check |doi= value (help). PMID 9661992.
  238. ↑ ออกุสต์ เด.:
    • Alzheimer Alois (1907). "Über eine eigenartige Erkrankung der Hirnrinde [About a peculiar disease of the cerebral cortex]". Allgemeine Zeitschrift fur Psychiatrie und Psychisch-Gerichtlich Medizin (in (เยอรมัน)). 64 (1–2): 146–148.CS1 maint: Unrecognized language (link)
    • Alzheimer Alois (1987). "About a peculiar disease of the cerebral cortex. By Alois Alzheimer, 1907 (Translated by L. Jarvik and H. Greenson)". Alzheimer Dis Assoc Disord. 1 (1): 3–8. PMID 3331112.
    • Maurer Ulrike, Maurer Konrad (2003). Alzheimer: the life of a physician and the career of a disease. New York: Columbia University Press. p. 270. ISBN 0-231-11896-1.
  239. ↑ Kraepelin Emil, Diefendorf A. Ross (translated by) (2007-01-17). Clinical Psychiatry: A Textbook For Students And Physicians (Reprint). Kessinger Publishing. p. 568. ISBN 1-4325-0833-4.
  240. ↑ Katzman R, Terry RD, Bick KL, eds. (1978). Alzheimer's Disease: Senile Dementia and Related Disorders. New York: Raven Press. p. 595. ISBN 978-0-89004-225-0.
  241. ↑ Boller F, Forbes MM (June 1998). "History of dementia and dementia in history: an overview". Journal of the Neurological Sciences. 158 (2): 125–33. doi:10.1016/S0022-510X(98)00128-2. PMID 9702682.
  242. ↑ Amaducci LA, Rocca WA, Schoenberg BS (November 1986). "Origin of the distinction between Alzheimer's disease and senile dementia: how history can clarify nosology". Neurology. 36 (11): 1497–9. doi:10.1212/wnl.36.11.1497. PMID 3531918.
  243. ↑ Allegri RF, Butman J, Arizaga RL, Machnicki G, Serrano C, Taragano FE, Sarasola D, Lon L (August 2007). "Economic impact of dementia in developing countries: an evaluation of costs of Alzheimer-type dementia in Argentina". International Psychogeriatrics. 19 (4): 705–18. doi:10.1017/S1041610206003784. PMID 16870037.
  244. ↑ Suh GH, Knapp M, Kang CJ (August 2006). "The economic costs of dementia in Korea, 2002". International Journal of Geriatric Psychiatry. 21 (8): 722–28. doi:10.1002/gps.1552. PMID 16858741.
  245. ↑ Wimo A, Jonsson L, Winblad B (2006). "An estimate of the worldwide prevalence and direct costs of dementia in 2003". Dementia and Geriatric Cognitive Disorders. 21 (3): 175–81. doi:10.1159/000090733. PMID 16401889.
  246. 1 2 3 Moore MJ, Zhu CW, Clipp EC (July 2001). "Informal costs of dementia care: estimates from the National Longitudinal Caregiver Study". The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences. 56 (4): S219–28. doi:10.1093/geronb/56.4.S219. PMID 11445614.
  247. ↑ Jönsson L, Eriksdotter Jönhagen M, Kilander L, Soininen H, Hallikainen M, Waldemar G, และคณะ (May 2006). "Determinants of costs of care for patients with Alzheimer's disease". International Journal of Geriatric Psychiatry. 21 (5): 449–59. doi:10.1002/gps.1489. PMID 16676288.
  248. 1 2 "The MetLife study of Alzheimer's disease: The caregiving experience" (PDF). MetLife Mature Market Institute. August 2006. Archived from the original (PDF) on 8 January 2011. สืบค้นเมื่อ 5 February 2011.
  249. ↑ Schneider J, Murray J, Banerjee S, Mann A (August 1999). "EUROCARE: a cross-national study of co-resident spouse carers for people with Alzheimer's disease: I – Factors associated with carer burden". International Journal of Geriatric Psychiatry. 14 (8): 651–61. doi:10.1002/(SICI)1099-1166(199908)14:8<651::AID-GPS992>3.0.CO;2-B. PMID 10489656.
  250. ↑ Murray J, Schneider J, Banerjee S, Mann A (August 1999). "EUROCARE: a cross-national study of co-resident spouse carers for people with Alzheimer's disease: II – A qualitative analysis of the experience of caregiving". International Journal of Geriatric Psychiatry. 14 (8): 662–67. doi:10.1002/(SICI)1099-1166(199908)14:8<662::AID-GPS993>3.0.CO;2-4. PMID 10489657.
  251. 1 2 Zhu CW, Sano M (2006). "Economic considerations in the management of Alzheimer's disease". Clinical Interventions in Aging. 1 (2): 143–54. doi:10.2147/ciia.2006.1.2.143. PMC 2695165. PMID 18044111.
  252. ↑ Gaugler JE, Kane RL, Kane RA, Newcomer R (April 2005). "Early community-based service utilization and its effects on institutionalization in dementia caregiving". The Gerontologist. 45 (2): 177–85. doi:10.1093/geront/45.2.177. PMID 15799982.
  253. ↑ Ritchie K, Lovestone S (November 2002). "The dementias". Lancet. 360 (9347): 1759–66. doi:10.1016/S0140-6736(02)11667-9. PMID 12480441.
  254. ↑ Brodaty H, Hadzi-Pavlovic D (September 1990). "Psychosocial effects on carers of living with persons with dementia". The Australian and New Zealand Journal of Psychiatry. 24 (3): 351–61. doi:10.3109/00048679009077702. PMID 2241719.
  255. ↑ Donaldson C, Tarrier N, Burns A (April 1998). "Determinants of carer stress in Alzheimer's disease". International Journal of Geriatric Psychiatry. 13 (4): 248–56. doi:10.1002/(SICI)1099-1166(199804)13:4<248::AID-GPS770>3.0.CO;2-0. PMID 9646153.
  256. ↑ Pusey H, Richards D (May 2001). "A systematic review of the effectiveness of psychosocial interventions for carers of people with dementia". Aging & Mental Health. 5 (2): 107–19. doi:10.1080/13607860120038302. PMID 11511058.
  257. ↑ Bayley J (2000). Iris: A Memoir of Iris Murdoch. London: Abacus. ISBN 978-0-349-11215-2. OCLC 41960006.
  258. ↑ Sparks N (1996). The notebook. Thorndike, Maine: Thorndike Press. p. 268. ISBN 978-0-7862-0821-0.
  259. ↑ Ogiwara H (2004). Ashita no Kioku (in ญี่ปุ่น). Tōkyō: Kōbunsha. ISBN 978-4-334-92446-1. OCLC 57352130.
  260. ↑ Munro A (2001). Hateship, Friendship, Courtship, Loveship, Marriage: Stories. New York: A.A. Knopf. ISBN 978-0-375-41300-1. OCLC 46929223.
  261. ↑ "Malcolm and Barbara: A love story". Dfgdocs. Archived from the original on 24 May 2008. สืบค้นเมื่อ 24 January 2008.
  262. ↑ "Malcolm and Barbara: A love story". BBC Cambridgeshire. Archived from the original on 10 November 2012. สืบค้นเมื่อ 2 March 2008.
  263. ↑ Plunkett J (7 August 2007). "Alzheimer's film-maker to face ITV lawyers". London: Guardian Media. Archived from the original on 15 January 2008. สืบค้นเมื่อ 24 January 2008.
  264. ↑ Cummings JL, Morstorf T, Zhong K (July 2014). "Alzheimer's disease drug-development pipeline: few candidates, frequent failures". Alzheimer's Research & Therapy. 6 (4): 37. doi:10.1186/alzrt269. PMC 4095696. PMID 25024750.
  265. ↑ Gutis, Phillip S. (22 March 2019). "An Alzheimer's Drug Trial Gave Me Hope, and Then It Ended". The New York Times. สืบค้นเมื่อ 25 March 2019.
  266. ↑ Lashuel HA, Hartley DM, Balakhaneh D, Aggarwal A, Teichberg S, Callaway DJ (November 2002). "New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease". The Journal of Biological Chemistry. 277 (45): 42881–90. doi:10.1074/jbc.M206593200. PMID 12167652.
  267. ↑ Dodel R, Neff F, Noelker C, Pul R, Du Y, Bacher M, Oertel W (March 2010). "Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence". Drugs. 70 (5): 513–28. doi:10.2165/11533070-000000000-00000. PMID 20329802. Archived from the original on 17 September 2011.
  268. ↑ Vaccination:
  269. ↑ "Study Evaluating ACC-001 in Mild to Moderate Alzheimers Disease Subjects". Clinical Trial. US National Institutes of Health. 11 March 2008. Archived from the original on 30 July 2013. สืบค้นเมื่อ 5 June 2008.
  270. ↑ "Study Evaluating Safety, Tolerability, and Immunogenicity of ACC-001 in Subjects with Alzheimer's Disease". US National Institutes of Health. Archived from the original on 29 October 2008. สืบค้นเมื่อ 5 June 2008.
  271. ↑ "Alzheimer's Disease Vaccine Trial Suspended on Safety Concern". Medpage Today. 18 April 2008. Archived from the original on 23 April 2008. สืบค้นเมื่อ 14 June 2008.
  272. ↑ "Bapineuzumab in Patients with Mild to Moderate Alzheimer's Disease/ Apo_e4 Non-carriers" (Clinical Trial). US National Institutes of Health. 29 February 2008. Archived from the original on 22 March 2008. สืบค้นเมื่อ 23 March 2008.
  273. ↑ Sperling RA, Jack CR, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ (July 2011). "Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup". Alzheimer's & Dementia. 7 (4): 367–85. doi:10.1016/j.jalz.2011.05.2351. PMC 3693547. PMID 21784348.
  274. ↑ "Safety, Tolerability and Efficacy Study to Evaluate Subjects with Mild Cognitive Impairment" (Clinical Trial). US National Institutes of Health. 11 March 2008. Archived from the original on 22 October 2008. สืบค้นเมื่อ 23 March 2008.
  275. ↑ "Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients with Early Alzheimer's Disease" (Clinical Trial). US National Institutes of Health. 13 January 2008. Archived from the original on 31 August 2008. สืบค้นเมื่อ 23 March 2008.
  276. ↑ Etanercept research:
  277. ↑ Wischik CM, Bentham P, Wischik DJ, Seng KM (July 2008). "Tau aggregation inhibitor (TAI) therapy with remberTM arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks". Alzheimer's & Dementia. 4 (4): T167. doi:10.1016/j.jalz.2008.05.438. สืบค้นเมื่อ 30 July 2008.
  278. ↑ Harrington C, Rickard J, Horsley D (July 2008). "Methylthioninium chloride (MTC) acts as a tau aggregation inhibitor (TAI) in a cellular model and reverses tau pathology in transgenic mouse models of Alzheimer's disease". Alzheimer's & Dementia. 4 (4): T120–21. doi:10.1016/j.jalz.2008.05.259.
  279. ↑ Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D (July 2008). "Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study". Lancet. 372 (9634): 207–15. doi:10.1016/S0140-6736(08)61074-0. PMID 18640457.
  280. ↑ Bezprozvanny I (October 2010). "The rise and fall of Dimebon". Drug News & Perspectives (Original article). 23 (8): 518–23. doi:10.1358/dnp.2010.23.8.1500435. PMC 3922928. PMID 21031168.
  281. ↑ "Pfizer And Medivation announce results from two phase 3 studies in Dimebon (latrepirdine*) Alzheimer's disease clinical development program (NASDAQ:MDVN)" (Press release). Archived from the original on 4 September 2012. สืบค้นเมื่อ 16 November 2012.
  282. ↑ Wendler A, Wehling M (March 2012). "Translatability scoring in drug development: eight case studies". Journal of Translational Medicine. 10 (10): 39. doi:10.1186/1479-5876-10-39. PMC 3330010. PMID 22397594.
  283. ↑ Baddeley TC, McCaffrey J, Storey JM, Cheung JK, Melis V, Horsley D, Harrington CR, Wischik CM (January 2015). "Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease". The Journal of Pharmacology and Experimental Therapeutics. 352 (1): 110–18. doi:10.1124/jpet.114.219352. PMID 25320049.
  284. ↑ Wischik CM, Harrington CR, Storey JM (April 2014). "Tau-aggregation inhibitor therapy for Alzheimer's disease". Biochemical Pharmacology. 88 (4): 529–39. doi:10.1016/j.bcp.2013.12.008. PMID 24361915.
  285. ↑ Marciniak R, Sheardova K, Cermáková P, Hudeček D, Sumec R, Hort J (2014). "Effect of meditation on cognitive functions in context of aging and neurodegenerative diseases". Frontiers in Behavioral Neuroscience. 8: 17. doi:10.3389/fnbeh.2014.00017. PMC 3903052. PMID 24478663.
  286. ↑ Larouche E, Hudon C, Goulet S (January 2015). "Potential benefits of mindfulness-based interventions in mild cognitive impairment and Alzheimer's disease: an interdisciplinary perspective". Behavioural Brain Research. 276 (276): 199–212. doi:10.1016/j.bbr.2014.05.058. PMID 24893317.
  287. 1 2 Martin C, Solís L, Concha MI, Otth C (June 2011). "[Herpes simplex virus type 1 as risk factor associated to Alzheimer disease]" [Herpes Simplex Virus Type 1 as Risk Factor Associated to Alzheimer Disease]. Revista Medica de Chile (in Spanish). 139 (6): 779–86. doi:10.4067/S0034-98872011000600013. PMID 22051760.CS1 maint: Unrecognized language (link)
  288. ↑ Wozniak MA, Mee AP, Itzhaki RF (January 2009). "Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques". The Journal of Pathology (Original study). 217 (1): 131–38. doi:10.1002/path.2449. PMID 18973185.
  289. ↑ Itzhaki RF (2014). "Herpes simplex virus type 1 and Alzheimer's disease: increasing evidence for a major role of the virus". Frontiers in Aging Neuroscience. 6: 202. doi:10.3389/fnagi.2014.00202. PMC 4128394. PMID 25157230.
  290. ↑ Itzhaki RF, Lathe R, Balin BJ, Ball MJ, Bearer EL, Braak H, และคณะ (2016). "Microbes and Alzheimer's Disease". Journal of Alzheimer's Disease. 51 (4): 979–84. doi:10.3233/JAD-160152. PMC 5457904. PMID 26967229. Archived from the original on 10 November 2016.
  291. ↑ Alonso R, Pisa D, Rábano A, Carrasco L (July 2014). "Alzheimer's disease and disseminated mycoses". European Journal of Clinical Microbiology & Infectious Diseases. 33 (7): 1125–32. doi:10.1007/s10096-013-2045-z. PMID 24452965.
  292. 1 2 Pisa D, Alonso R, Rábano A, Rodal I, Carrasco L (October 2015). "Different Brain Regions are Infected with Fungi in Alzheimer's Disease". Scientific Reports. 5: 15015. Bibcode:2015NatSR...515015P. doi:10.1038/srep15015. PMC 4606562. PMID 26468932.
  293. ↑ "Fungus, the bogeyman". The Economist. 22 October 2015. Archived from the original on 8 August 2017.
  294. ↑ Kumar DK, Choi SH, Washicosky KJ, Eimer WA, Tucker S, Ghofrani J, Lefkowitz A, McColl G, Goldstein LE, Tanzi RE, Moir RD (May 2016). "Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer's disease". Science Translational Medicine. 8 (340): 340ra72. doi:10.1126/scitranslmed.aaf1059. PMC 5505565. PMID 27225182.
  295. ↑ Kolata, Gina (25 May 2016). "Could Alzheimer's Stem From Infections? It Makes Sense, Experts Say". The New York Times. Archived from the original on 4 February 2017.
  296. ↑ "Alzheimer's culprit may fight other diseases". Science News. 16 June 2016. Archived from the original on 26 May 2016.
  297. ↑ Jaunmuktane Z, Mead S, Ellis M, Wadsworth JD, Nicoll AJ, Kenny J, และคณะ (September 2015). "Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy". Nature. 525 (7568): 247–50. Bibcode:2015Natur.525..247J. doi:10.1038/nature15369. PMID 26354483.
  298. ↑ Abbott A (September 2015). "Autopsies reveal signs of Alzheimer's in growth-hormone patients". Nature. 525 (7568): 165–66. Bibcode:2015Natur.525..165A. doi:10.1038/525165a. PMID 26354460.
  299. ↑ Dougall NJ, Bruggink S, Ebmeier KP (2004). "Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia". The American Journal of Geriatric Psychiatry. 12 (6): 554–70. doi:10.1176/appi.ajgp.12.6.554. PMID 15545324.
  300. ↑ Carpenter AP, Pontecorvo MJ, Hefti FF, Skovronsky DM (August 2009). "The use of the exploratory IND in the evaluation and development of 18F-PET radiopharmaceuticals for amyloid imaging in the brain: a review of one company's experience". The Quarterly Journal of Nuclear Medicine and Molecular Imaging. 53 (4): 387–93. PMID 19834448.
  301. ↑ Leung K (8 April 2010). "(E)-4-(2-(6-(2-(2-(2-(18F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methyl benzenamine [[18F]AV-45]". Molecular Imaging and Contrast Agent Database. Archived from the original on 7 June 2010. สืบค้นเมื่อ 24 June 2010.
  302. ↑ Rabinovici GD, Jagust WJ (2009). "Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo". Behavioural Neurology. 21 (1): 117–28. doi:10.3233/BEN-2009-0232. PMC 2804478. PMID 19847050. Archived from the original on 30 July 2013.
  303. ↑ O'Brien JT (December 2007). "Role of imaging techniques in the diagnosis of dementia". The British Journal of Radiology. 80 Spec No 2 (Spec No 2): S71–77. doi:10.1259/bjr/33117326. PMID 18445747.
  304. ↑ "FDA Panel Recommends Conditional Approval for PET Agent". Imaging Technology News. 2011-01-21. สืบค้นเมื่อ 2019-06-17.
  305. ↑ Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, และคณะ (January 2011). "Use of florbetapir-PET for imaging beta-amyloid pathology". JAMA. 305 (3): 275–83. doi:10.1001/jama.2010.2008. PMID 21245183.
  306. ↑ "Amyvid". Community register of medicinal products for human use. European Community. 17 January 2013. สืบค้นเมื่อ 18 April 2018.
  307. ↑ Chong MS, Sahadevan S (September 2005). "Preclinical Alzheimer's disease: diagnosis and prediction of progression". The Lancet. Neurology. 4 (9): 576–79. doi:10.1016/s1474-4422(05)70168-x. PMID 16109364.
  308. 1 2 Sharma N, Singh AN (July 2016). "Exploring Biomarkers for Alzheimer's Disease". Journal of Clinical and Diagnostic Research (Review). 10 (7): KE01–06. doi:10.7860/JCDR/2016/18828.8166. PMC 5020308. PMID 27630867.

แหล่งที่มา

WikiPedia: โรคอัลไซเมอร์ http://www.sbgg.org.br/profissional/artigos/pdf/de... http://www.scielo.br/scielo.php?script=sci_arttext... http://www.abstractsonline.com/viewer/viewAbstract... http://adisonline.com/drugs/Abstract/2010/70050/In... http://works.bepress.com/cgi/viewcontent.cgi?artic... http://www.dfgdocs.com/Directory/Titles/700.aspx http://www.diagnosticimaging.com/news/display/arti... http://www.diseasesdatabase.com/ddb490.htm http://www.emedicine.com/neuro/topic13.htm http://www.frx.com/pi/namenda_pi.pdf